P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

Sublingual Sufentanil Shows Mixed Results in Phase II Pain Study

Higher dose meets primary endpoint, but lower dose doesn’t (Apr. 24)

In a placebo-controlled, dose-finding, phase II study, a higher dose (30 mcg) of the investigational single-dose sublingual sufentanil NanoTab for acute pain (ARX-04, AcelRx Pharmaceuticals) successfully met its primary endpoint, whereas a lower dose (20 mcg) did not.

The results showed that patients receiving the 30-mcg sufentanil dose, administered by a healthcare professional no more frequently than once per hour, experienced significantly greater pain reduction, as measured by the Summed Pain Intensity Difference to baseline, during the 12-hour study period (SPID-12) compared with placebo-treated patients (P = 0.003). Patients treated with the 20-mcg dose of sublingual sufentanil did not achieve SPID-12 scores that differed from those of the placebo group.

The study randomly assigned 101 patients to receive sufentanil 30 mcg, sufentanil 20 mcg, or placebo following bunionectomy surgery. The intent-to-treat (ITT) population had an average age of 42.5 years and was evenly balanced for males and females (51% vs. 49%, respectively) and for ethnicity (54% Caucasian vs. 46% non-Caucasian). Ninety-one percent of the enrolled patients completed the full 12-hour study period.

SPID-12 scores were +6.53 for patients treated with sufentanil 30 mcg versus –7.12 for placebo-treated patients (P = 0.003).

Adverse events (AEs) were generally mild-to-moderate in severity. Two patients treated with the 30-mcg dose dropped out of the study because of AEs. One patient’s discontinuation was considered to be probably related to the study drug.

ARX-04 is a product candidate in development for the treatment of moderate-to-severe acute pain. It consists of sufentanil, a high-therapeutic-index opioid, in a NanoTab, which allows rapid sublingual absorption when the tab is placed under the tongue.

Source: AcelRx Pharmaceuticals; April 24, 2013.

More stories